Outcome and prognostic factors for osteosarcoma of the maxilla, mandible, or calvarium in dogs: 183 cases (1986-2012)

J Am Vet Med Assoc. 2014 Oct 15;245(8):930-8. doi: 10.2460/javma.245.8.930.

Abstract

Objective: To describe the biological behavior, clinical outcome, and prognostic factors of osteosarcoma of the maxilla, mandible, or calvarium in dogs.

Design: Retrospective case series.

Animals: 183 client-owned dogs with osteosarcoma of the maxilla, mandible, or calvarium.

Procedures: Medical records for dogs treated for osteosarcoma of the maxilla, mandible, or calvarium from 1986 through 2012 were reviewed. Dogs with a histopathologic diagnosis of osteosarcoma and treated for a primary tumor arising from these bones of the head were included.

Results: Mean age was 9.3 years, and body weight was 31.8 kg (70.0 lb). Most dogs (124/183 [67.8%]) were purebred, and the most common primary tumor site was the maxilla (80 [43.7%]). Treatments included palliative medical treatment only (11/183 [6.0%]), coarsely fractionated radiation therapy (RT; 12 [6.6%]), fractionated or stereotactic RT (18 [9.8%]), surgery (135 [73.8%]), and both surgery and fractionated RT (7 [3.8%]). Eighty-three (45.4%) dogs received adjuvant chemotherapy. Local recurrence or progression occurred in 80 of 156 (51.3%) dogs, and 60 of 156 (38.5%) dogs developed distant metastases. Median survival time for all dogs was 239 days. Dogs that underwent surgery had a median survival time of 329 days. Histologically tumor-free surgical margins were associated with significantly decreased hazards of progression or recurrence (hazard ratio [HR], 0.4) and death (HR, 0.5). Dogs with osteosarcoma of the calvarium had a significantly greater hazard of local recurrence or progression (HR, 2.0).

Conclusions and clinical relevance: In this study, tumor excision in dogs with histologically tumor-free margins resulted in better local control and longer survival time than did other treatment types.

MeSH terms

  • Animals
  • Antineoplastic Agents / therapeutic use
  • Dog Diseases / therapy*
  • Dogs
  • Mandibular Neoplasms / therapy
  • Mandibular Neoplasms / veterinary*
  • Maxillary Neoplasms / therapy
  • Maxillary Neoplasms / veterinary*
  • Osteosarcoma / therapy
  • Osteosarcoma / veterinary*
  • Radiotherapy / veterinary
  • Retrospective Studies
  • Risk Factors
  • Skull Neoplasms / therapy
  • Skull Neoplasms / veterinary*
  • Treatment Outcome

Substances

  • Antineoplastic Agents